Evotec receives pre-clinical milestone as part of its discovery alliance with Boehringer Ingelheim

09-Jul-2013 - Germany

Evotec AG announced that its research alliance with Boehringer Ingelheim has reached a milestone in June triggering revenues of EUR 1.5 m to Evotec. The milestone was for the transition of a pain molecule into pre-clinical development.

Dr Mario Polywka, Chief Operating Officer of Evotec commented: 'This is the eighteenth milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of a compound into pre-clinical development. We are pleased the collaborative efforts of teams from Evotec and Boehringer Ingelheim continue to drive value for both our organisations.'

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...